SCHEMBL3932995

SCHEMBL3932995

NCc1cc(C(N)=O)no1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 3/20 0.43
CYP2C19 P33261 2/20 0.41
CYP2E1 P05181 1/20 0.41
CYP2A6 P11509 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2B6 P20813 1/20 0.41
LMNA P02545 1/20 0.38
IGF1R P08069 1/20 0.37
FGFR1 P11362 1/20 0.37
KDR P35968 1/20 0.37
RAB9A P51151 5/20 0.35
HPGD P15428 1/20 0.35
NPC1 O15118 4/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
ALDH1A1 P00352 2/20 0.33
S1PR1 P21453 2/20 0.33
S1PR3 Q99500 2/20 0.33
TSHR P16473 2/20 0.33
HDAC6 Q9UBN7 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4010638 0.98 NOTUM (0.42) NOTUMCYP2C19CYP2E1CYP2A6CYP2C9
Trifluoroacetic Acid SCHEMBL3938515 0.88 NOTUM (0.39) NOTUMCYP2C19CYP2E1CYP2A6CYP2C9
SCHEMBL3823349 0.83 NOTUM (0.47) NOTUMCYP2C19CYP2E1CYP2A6CYP2C9
SCHEMBL345666 0.83 NOTUM (0.43) NOTUMCYP2C19LMNAIGF1RFGFR1
SCHEMBL5988237 0.82 ALDH1A1 (0.41) LMNAIGF1RFGFR1KDRRAB9A
SCHEMBL2619071 0.82 THRB (0.48) IGF1RFGFR1KDRRAB9AHPGD
SCHEMBL23530111 0.77 MRGPRX4 (0.42) IGF1RFGFR1KDRRAB9ANPC1
SCHEMBL2797765 0.77 IGF1R (0.39) LMNAIGF1RFGFR1KDRRAB9A
SCHEMBL2791167 0.77 ALDH1A1 (0.56) LMNARAB9AHPGDNPC1SMN1; SMN2
SCHEMBL4009260 0.77 RAB9A (0.44) RAB9AHPGDNPC1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101501030-A Pyrimidine derivatives useful in the treatment of cancer ASTRAZENECA AB (SE) 2009-08-05 CN disclosed
EP-2044063-A1 PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER Astra Zeneca AB (SE) 2009-04-08 EP disclosed
WO-2008001070-A1 PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-01-03 WO disclosed
US-20080004302-A1 Novel Compounds ASTRAZENECA AB (SE) 2008-01-03 US disclosed
US-7144902-B1 Prodrugs of thrombin inhibitors ABBOTT GMBH & CO. KG (DE) 2006-12-05 US disclosed
US-6740647-B1 AMIDINES AND HYDROXYAMIDINE DERIVATIVES ABBOTT GMBH & CO., KG (DE) 2004-05-25 US disclosed
CN-1355810-A Prodrugs of thrombin inhibitors BASF AG (DE) 2002-06-26 CN disclosed
US-6114358-A Thrombin inhibitors BASF AKTIENGESELLSCHAFT (DE) 2000-09-05 US disclosed
CN-1228783-A Novel thrombin inhibitors BASF AG (DE) 1999-09-15 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004302-A1 Novel Compounds CYP11B2, CYP11B1, CYP46A1 NOTUM 1823/4885CYP2C19 69/4885CYP2E1 269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.